CD4 and neoplasm: In both tumor models, GPR171 blockade proportionally increased intratumoral CD3+ T cells and CD8 + T cells in CD45+ immune cells and increased the ratio of CD8+ to CD4+ T cells within tumors (Supplementary Fig. 6c, d).